Gregory A. Otterson, MD, of The Ohio State University Comprehensive Cancer Center and the James Cancer Hospital and Solove Research Institute, discusses the evolution of lung cancer treatment from adjuvant chemotherapy to immunotherapy and the clinical trials underway.
Peter G. Shields, MD, of The Ohio State University Comprehensive Cancer Center and the James Cancer Hospital and Solove Research Institute, discusses the new NCCN Guidelines for helping patients with cancer to stop smoking. Counseling is a critical part of these new recommendations.
Melinda Telli, MD, of Stanford Cancer Institute, discusses the TNT trial for triple-negative breast cancer and the results reported at the San Antonio Breast Cancer Symposium.
Mary Lou Smith, JD, MBA, of the Research Advocacy Network, discusses, from the perspective of a patient advocate, the value of the NCCN guidelines and the impact they have made on cancer care.
Hans Gerdes, MD, of Memorial Sloan Kettering Cancer Center, discusses a new approach to the management of early-stage esophageal cancers with endoscopic resections.
Thomas A. D’Amico, MD, of Duke Cancer Institute, discusses the superior efficacy of thoracoscopic lobectomy. This minimally invasive procedure is used in only 50% of lung cancer surgeries in the United States, in 30% of procedures in Asia, and in as few as 10% to 20% of procedures in Europe.
